Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11836733

Selection effects in randomized trials with count data.

Richard J Cook·Wei Wei
View original source ↗Export metadata ↓

Abstract

Selection criteria are specified in clinical trials to define the study population from which the sample will be obtained. It is common for one of these criteria to be based on historical or baseline measurements of the clinical sign or symptom that will serve as the response variable in the trial. The effect of such selection criteria has been studied extensively for normally distributed responses, but less is known about the situation in which the response is a count or a possibly recurrent event. In this paper we examine the bias and relative efficiency of some common methods of analysis for count data in the presence of selection criteria. The investigation is carried out using asymptotic theory pertaining to misspecified models and by simulation. Applications involving data from an epilepsy trial and a study of transient myocardial ischaemia illustrate the effect of ignoring the selection mechanism.

Explore related subjects

AnticonvulsantsComputer SimulationElectrocardiography, AmbulatoryEpilepsyHumansModels, BiologicalMyocardial IschemiaRandomized Controlled Trials as TopicSeizuresSelection Biasgamma-Aminobutyric AcidJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Richard J Cook, Wei Wei. 2002-02-28. Selection effects in randomized trials with count data.. https://doi.org/10.1002/sim.1014

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

The treatment of epilepsy in developing countries: where do we go from here?

Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent noncommunicable diseases. As the understanding of its physical and social burden has increased it has moved higher up the world health agenda. Over four-fifths of the 50 million people with epilepsy are thought to be in developing countries; much of this condition results from preventable causes. Around 90% of people with epilepsy in developing countries are not receiving appropriate treatment. Consequently, people with epilepsy continue to be stigmatized and have a lower quality of life than people with other chronic illnesses. However, bridging the treatment gap and reducing the burden of epilepsy is not straightforward and faces many constraints. Cultural attitudes, a lack of prioritization, poor health system infrastructure, and inadequate supplies of antiepileptic drugs all conspire to hinder appropriate treatment. Nevertheless, there have been successful attempts to provide treatment, which have shown the importance of community-based approaches and also indicate that provision for sustained intervention over the long term is necessary in any treatment programme. Approaches being adopted in the demonstration projects of the Global Campaign Against Epilepsy--implemented by the International League Against Epilepsy, the International Bureau for Epilepsy, and the World Health Organization--may provide further advances. Much remains to be done but it is hoped that current efforts will lead to better treatment of people with epilepsy in developing countries.

Anticonvulsants↗
PubMed2002

A HPLC assay for coating integrity of topiramate sprinkle formulation.

A HPLC method has been developed for the determination of coating integrity of topiramate sprinkle formulation. This method determines the completeness of the sprinkle coating and, indirectly, the completeness of taste masking of the product. This method utilizes a sample preparation where the sprinkles are placed in a specially designed stainless steel basket equipped with a screen, 25-mesh size, at the bottom. Water is used to solubilize any incompletely coated drug. The aqueous solution is analyzed for topiramate using a phenyl column in the reversed-phase mode, isocratic elution, and refractive index detection. This analytical method, for recovered topiramate, provides an indirect measure of drug taste-masking in the sprinkle formulation. It was also used in formulation selection by screening sprinkles beads that contained different amounts of coating to see which formula can best mask the taste with an acceptable level of exposed topiramate drug substance. This method has been validated to meet FDA validation guidelines.

Anticonvulsants↗